LRRK2 and Parkinson disease: Additionally, TPC2 can associate with the leucine-rich repeat kinase 2 (LRRK2), mutations in which are linked to late-onset Parkinson’s disease [20], and the mammalian target of rapamycin (mTOR), a serine/threonine protein kinase that when hyperactivated leads to increased growth and proliferation [10].